secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001193125-26-205008
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes Q1 revenue $392.9M; GAAP net loss $66.5M after Avadel acquisition costs
--------------------------------------------------------------------------------

- Q1 total revenues $392.9M, up 28% YoY; GAAP net loss $66.5M vs. income of $22.5M in Q1 2025.
- Adjusted EBITDA $80.3M, up from $45.6M YoY; LUMRYZ contributed $39.5M post-Avadel close on Feb 12.
- Full-year 2026 GAAP net loss guidance improved to ($70)-($90)M from ($115)-($135)M; total revenue outlook unchanged.
- Avadel acquisition closed in Feb; used $775M cash and $1.525B term loans; cash balance now $538M.
- Initiated Phase 3 Brilliance studies for alixorexton in narcolepsy type 1 and type 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000119312526205008/0001193125-26-205008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000119312526205008/alks-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-205008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer